Xenetic Biosciences Q1 net loss $0.9M; cash $12M; Takeda royalties up 55.7%

Xenetic Biosciences, Inc.

2023-Q1 EPS reported -$0.06 revenue$605,844

Net loss of $0.9M for Q1 2023; R&D expenses down 46% to $0.6M from $1.1M.
Royalty payments from Takeda sublicense increased 55.7% to $0.6M.
Ended quarter with $12.0M cash; advancing DNase oncology program.
Entered collaboration with Scripps Research Institute for DNase and CAR T programs.
Appointed Scott N. Cullison and Reid P. Bissonnette to support DNase platform.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Xenetic Biosciences, Inc. reported three months ended March 31, 2023 results: net income approximately $0.9 million.

Period: three months ended March 31, 2023
Net income: approximately $0.9 million
Result: reported results

Exact text from the filing

Net loss for the quarter ended March 31, 2023 was approximately $0.9 million.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Xenetic Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-003203

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.